Unión Europea -
esloveno -
EMA (European Medicines Agency)
veyvondi
baxalta innovations gmbh - vonicog alfa - von willebrand bolezni - antihemoragije - veyvondi je navedeno v odrasle (starost 18 let in starejših), von willebrand bolezni (vwd), ko desmopressin (ddavp) zdravljenje sam je neučinkovita ali ni označeno za - zdravljenje krvavitve in kirurške krvavitve - preprečevanje kirurške krvavitve. veyvondi ne sme uporabljati pri zdravljenju hemofilija a.
Unión Europea -
esloveno -
EMA (European Medicines Agency)
gencebok
gennisium pharma - kofein citrat - apnea - psychoanaleptics, - zdravljenje primarne apnoea prezgodnje novorojenčkov.
Unión Europea -
esloveno -
EMA (European Medicines Agency)
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
Unión Europea -
esloveno -
EMA (European Medicines Agency)
kapruvia
vifor fresenius medical care renal pharma france - difelikefalin - pruritus - vsi drugi terapevtski izdelki - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.
Unión Europea -
esloveno -
EMA (European Medicines Agency)
melatonin neurim
rad neurim pharmaceuticals eec sarl - melatonin - motnje v zvezi s spanjem in vzdrževanjem - psiholeptiki - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Unión Europea -
esloveno -
EMA (European Medicines Agency)
bimervax
hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - cepiva - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.
